3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Primary Myelofibrosis
6
Myeloproliferative Disorders
6
Polycythemia Vera
5
Pancreatic Neoplasms
2
Neoplasms
2
Hematologic Diseases
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Lymphoma, Follicular
1
Graft vs Host Disease
1
Bronchiolitis Obliterans Syndrome
1
Bone Marrow Diseases
1
Interventions
Rituximab
67
Cyclophosphamide
39
Vincristine
33
Prednisone
31
Doxorubicin
25
Lenalidomide
18
Radiotherapy
16
Bendamustine Hydrochloride
14
Peripheral Blood Stem Cell Transplantation
10
Filgrastim
10
Etoposide
10
Prednisolone
8
tofacitinib
7
obinutuzumab
6
ibritumomab tiuxetan
6
fludarabine
6
VAP-cyclo protocol
6
Mitoxantrone
6
Methylprednisolone
6
Deoxycholic Acid
6
Cytarabine
6
Melphalan
5
Dexamethasone
5
Carmustine
5
ibrutinib
4
fludarabine phosphate
4
R-CHOP protocol
4
Methotrexate
4
Interferon-alpha
4
Idarubicin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, Follicular
×
ruxolitinib
×
Clear all
NCT04934670
2024-08-27
2002
Xenikos
Phase 3
Terminated
12 enrolled
12 charts